A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy

Clinical Infectious Diseases

Volumn 45, Issue 5, 2007, Pages 527-533

  Sunenshine, Rebecca H ^a   Tan, Esther T ^a,b   Terashita, Dawn M ^c   Jensen, Bette J ^a   Kacica, Marilyn A ^d   Sickbert Bennett, Emily E ^g   Noble Wang, Judith A ^a   Palmieri, Michael J ^f   Bopp, Dianna J ^e   Jernigan, Daniel B ^a   Kazakova, Sophia ^a   Bresnitz, Eddy A ^b   Tan, Christina G ^b   McDonald, L Clifford ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NEW JERSEY DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

^c LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES   (United States)

^d NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^e WADSWORTH CENTER   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUROSEMIDE; MAGNESIUM SULFATE; MIDAZOLAM; RANITIDINE;

ADULT; AGED; ARTICLE; BACTERIUM CULTURE; BLOOD FLOW; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG CONTAMINATION; ENTEROBACTER INFECTION; ENVIRONMENTAL FACTOR; EPIDEMIC; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; ISOLATION PROCEDURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PHARMACY; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RISK FACTOR; SERRATIA MARCESCENS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; CARDIAC SURGICAL PROCEDURES; CARDIOVASCULAR AGENTS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CROSS INFECTION; DISEASE OUTBREAKS; DRUG COMPOUNDING; DRUG CONTAMINATION; FEMALE; HUMANS; LOS ANGELES; MAGNESIUM SULFATE; MALE; MIDDLE AGED; NEW JERSEY; RISK FACTORS; SERRATIA INFECTIONS; SERRATIA MARCESCENS; UNITED STATES;

EID: 34548232135     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520664     Document Type: Article

References (24)

1. Galson S. Statement before the senate committee on health, education, labor and pensions hearing on "Federal and State Role in Pharmacy Compounding and Reconstitution: Exploring the Right Mix to Protect Patients." Washington, DC: 2003. Available at: http://www.fda.gov/ola/ 2003/pharmacycompound1023.html. Accessed 30 May 2006.
2. Kastango ES, Bradshaw BD. USP chapter 797: establishing a practice standard for compounding sterile preparations in pharmacy. Am J Health Syst Pharm 2004; 61:1928-38.
3. Centers for Disease Control and Prevention. Exophiala infection from contaminated injectable steroids prepared by a compounding pharmacy - United States. MMWR Morb Mortal Wkly Rep 2002; 51:1109-12.
4. Civen RH, Alexander RC, Brunner W, et al. An outbreak of Serratia marcescens infections following epidural and intra-articular steroid injections associated with betamethasone compounded at a community pharmacy. In: Program and abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001:201.
5. Perz JF, Craig AS, Stratton CW, Bodner SJ, Phillips WE Jr, Schaffner W. Pseudomonas putida septicemia in a special care nursery due to contaminated flush solutions prepared in a hospital pharmacy. J Clin Microbiol 2005; 43:5316-8.
6. Jones TF, Feler CA, Simmons BP, et al. Neurologic complications including paralysis after a medication error involving implanted intrathecal catheters. Am J Med 2002; 112:31-6.
7. Held MR, Begier EM, Beardsley DS, et al. Life-threatening sepsis due to Burkholderia cepacia from contaminated intravenous flush solutions prepared by a compounding pharmacy in another state. Pediatrics 2006; 118:e212-5.
8. Grohskopf LA, Roth VR, Feikin DR, et al. Serratia liquefaciens bloodstream infections from contamination of epoetin alfa at a hemodialysis center. N Engl J Med 2001; 344:1491-7.
9. Ehrenkranz NJ, Cleary T. Serratia marcescens contaminated disinfectants. Lancet 1981; 1:1154-5.
10. Nakashima AK, Highsmith AK, Martone WJ. Survival of Serratia marcescens in benzalkonium chloride and in multiple-dose medication vials: relationship to epidemic septic arthritis. J Clin Microbiol 1987; 25:1019-21.
11. Nakashima AK, McCarthy MA, Martone WJ, Anderson RL. Epidemic septic arthritis caused by Serratia marcescens and associated with a benzalkonium chloride antiseptic. J Clin Microbiol 1987; 25:1014-8.
12. Vigeant P, Loo VG, Bertrand C, et al. An outbreak of Serratia marcescens infections related to contaminated chlorhexidine. Infect Control Hosp Epidemiol 1998; 19:791-4.
13. Sartor C, Jacomo V, Duvivier C, Tissot-Dupont H, Sambuc R, Drancourt M. Nosocomial Serratia marcescens infections associated with extrinsic contamination of a liquid nonmedicated soap. Infect Control Hosp Epidemiol 2000; 21:196-9.
14. Hejazi A, Aucken HM, Falkiner FR. Epidemiology and susceptibility of Serratia marcescens in a large general hospital over an 8-year period. J Hosp Infect 2000; 45:42-6.
15. Passaro DJ, Waring L, Armstrong R, et al. Postoperative Serratia marcescens wound infections traced to an out-of-hospital source. J Infect Dis 1997; 175:992-5.
16. CDC definitions for nosocomial infections, 1988. Am Rev Respir Dis 1989; 139:1058-9.
17. Wrestler JC, Lipes BD, Birren BW, Lai E. Pulsed-field gel electrophoresis. Methods Enzymol 1996; 270:255-72.
18. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33:2233-9.
19. NCCLS. Performance standards for antimicrobial susceptibility tests. Wayne, PA: NCCLS, 2004; 24:M100-S14.
20. 4 in 5% dextrose because of a potential lack of sterility assurance. Available at: http:// www.fda.gov/oc/po/firmrecalls/pharmedium04_05html. Accessed 21 February 2006.
21. Guidance for FDA staff and industry compliance policy guides manual section 460.200 pharmacy compounding. Available at: http:// www.fda.gov/OHRMS/ DOCKETS/98fr/02D-0242_gdl0001.pdf. Accessed 6 February 2006.
22. Allen LV Jr. Contemporary pharmaceutical compounding. Ann Pharmacother 2003; 37:1526-8.
23. Food and Drug Administration. Prescription and over-the-counter drug product list. 17th ed. Washington, D.C. Cumulative supplement number 6, 1997. Available at: http://www.pharmwatch.org/comp/ cpg.shtml. Accessed 30 May 2006.
24. Pharmaceutical compounding - sterile preparations. In: The United States pharmacopeia, 27th rev., and the national formulary. 22nd ed. Rockville, MD: United States Pharmacopeial Convention, 2004: 2350-70.